Anticoagulant Response to Agkistrodon Contortrix Venom (ACV test): a New Global Test to Screen for Defects in the Anticoagulant Protein C Pathway

Summary

As specific assays used to identify defects in the protein C (PC) anticoagulant pathway are laborious and expensive, we describe here a global test to screen for these defects. This assay is expressed as the ratio of two activated partial thomboplastin times, one in the absence and one in the presence of 0,125 U/ml of the PC activator of Agkistrodon contortrix venom (ACV). Eight of the 168 healthy volunteers of the control group exhibited an ACV ratio below the lower normal limit of 3.37 [6 subjects with the mutation Arg 506 to Gin in their factor V gene (FV R506Q) and one with PS deficiency]. 128 patients who have had at least one episode of deep-vein thrombosis were retrospectively studied. All patients carrying FV Q506R (n = 48), PC deficiency (n = 14) or combined defects, i. e. FV Q506R and PC deficiency (n = 4) or FV Q506R and PS deficiency (n = 3), had ACV ratios < 3.37. PS deficient plasmas (n = 20) exhibited ACV ratios which overlapped normal range. ACV ratios of one out of seven patients with antithrombin deficiency, and 10% of patients without identified defect in the PC anticoagulant pathway (n = 30) were < 3.37. An ACV ratio raised to 3.70 could lead to a test identifying all patients with a defect in the PC anticoagulant pathway.

• References

• 1 Gladson CL, Scharrer I, Hack V, Beck KH, Griffin JH. The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemost 1988; 59: 18-22
• 2 Ben-Tal O, Zivelin A, Seligsohn U. The relative frequency of hereditary thrombotic disorders among 107 patients with thrombophilia in Israel. Thromb Haemost 1989; 61: 50-54
• 3 Tabemero MD, Thomas JF, Alberca I, Orfao A, Borrasca AL, Vicente V. Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. Am J Hematol 1991; 36: 249-54
• 4 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008
• 5 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67
• 6 Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506Gln in factor Va. Lancet 1994; 343: 1362
• 7 Voorberg J, RoelseE J, Koopman R. Association of idiopathic venous thromboembolism with single point mutation at Arg⁵⁰⁶ of factor V. Lancet 1994; 343: 1535-1536
• 8 Zöller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994; 343: 1536-1538
• 9 Zöller B, Svensson PJ, He X, Dahlböck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-2524
• 10 Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in a majority of thrombophilic patients. Blood 1993; 82: 1989-1993
• 11 Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor response to activated protein C: Leiden thrombophilia study. Lancet 1993; 342: 1503-1506
• 12 Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-522
• 13 Cadroy Y, Sié P, Boneu B. Frequency of a defective response to activated protein C in patients with a history of venous thrombosis. Blood 1994; 83: 2008-2009
• 14 Halmayer WM, Haushofer A, Schon R, Fischer M. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coag Fibrinol 1994; 5: 51-57
• 15 Ridker PM, Hennekens CH, Lindpainter K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-917
• 16 Pabinger I, Allaart CF, Hermans J, Briët E, Bertina RM. and the Protein C Transmitter Study Group. Hereditary protein C-deficiency: Laboratory values in transmitters and guidelines for the diagnostic procedure. Report on a study of the SSC Subcommittee on protein C and protein S. Thromb Haemost 1992 68. 470-474
• 17 Boyer-Neumann C, Bertina RM, Tripodi A, D’Angelo A, Wolf M, Vigano D’Angelo S, Mannucci PM, Meyer D, Larrieu MJ. Comparison of functional assays for protein S: European collaborative study of patients with congenital and acquired deficiency. Thromb Haemost 1993; 70: 946-950
• 18 Faioni EM, Franchi F, Asti D, Sacchi E, Bernardi F, Mannucci PM. Resistance to activated protein C in nine thrombophilic families: Interference in a protein S functional assay. Thromb Haemost 1993; 70: 1067-1071
• 19 de Ronde H, Bertina RM. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994; 72: 880-886
• 20 Stocker K, Fischer H, Meier J, Brogli M, Svendsen L. Characterization of the protein C activator Protac® from the venom of the southern copperhead (Agkistrodon Contortrix) snake. Toxicon 1987; 25: 239-252
• 21 Exner T, Vaasjoki R. Characterisation and some properties of the protein C activator from Agkistrodon Contortrix Contortrix venom. Thromb Haemost 1988; 59: 40-44
• 22 Kraus M, Noah M, Fickenscher K. The PCAT - A simple screening assay for assessing the functionality of the protein C anticoagulant pathway. Thromb Res 1995; 79: 217-222
• 23 Reed AH, Henry RJ, Mason WB. Influence of statistical method used on the resulting estimate of normal range. Clin Chem 1971; 17: 275-284
• 24 Martinolli JL, Stocker K. Fast functional protein C assay using Protac®, a novel protein C activator. Thromb Res 1986; 43: 253-264
• 25 Nathan IV, Han Ping, Pradhan MM. Protein C functional assay using snake venom activator. Thromb Res 1987; 43: 253-264
• 26 Suzuki K, Nishioka J. Plasma protein S activity using Protac, a snake venom derived activator of protein C. Thromb Res 1988; 49: 241-251
• 27 Heeb MJ, Kojima Y, Greengard JS, Griffin JH. Activated protein C resistance: molecular mechanism based on studies using purified Gln506-factor V. Blood 1995; 85: 3405-3411
• 28 Dahlbäck B. Resistance to activated protein C, the Arg⁵⁰⁶ to Gin mutation in the factor V gene, and venous thrombosis. Functional tests and DNA-based assays, pros and cons. Thromb Haemost 1995; 73: 739-742.
• 29 Koedam JA, Meijers JCM, Sixma JJ, Bouma BN. Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest 1988; 82: 1236-1240
• 30 Bertina R, Reitsma PH, Rosendaal FR, Vandenbroucke JP. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemost 1995; 74: 449-453
• 31 Koster T, Blann AD, Briët E, Vandenbrouck JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurence of deep-vein thrombosis. Lancet 1995; 345: 152-155
• 32 Trossaërt M, Conard J, Horellou MH, Samama MM. Influence of storage conditions on activated protein C resistance assay. Thromb Haemost 1995; 73: 163-164
• 33 Rosen S, Johansson K, Lindberg K, Dahlbäck B. Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals. Thromb Haemost 1994; 72: 255-260
• 34 Henkens CMA, Bom VJJ, Seinen AJ, van der Meer J. Sensitivity to activated protein C; Influence of oral contraceptives and sex. Thromb Haemost 1995; 73: 402-404
• 35 Tait RC, Walker ID, Islam SIAM, McCall F, Conkie JA, Wight M, Mitchell R, Davidson JF. Protein C activity in healthy volunteers - Influence of age, sex, smoking and oral contraceptive. Thromb Haemost 1993; 70: 281-285